Remdesivir appears to be the most promising.
Remdesivir is a novel antiviral drug developed
Later, Remdesivir also demonstrated possible inhibition of other
Clinical improvement was observed in patients treated with compassionate-use Remdesivir.
Interestingly, the nucleotide analogue Remdesivir is known to suppress CoV replication
Remdesivir is one of most promising anti-SARS-CoV-2 agents
to be tested in clinical trials.
Later, Remdesivir also demonstrated possible inhibition of other
single stranded RNA viruses including MERS and SARS viruses.
Remdesivir is a novel antiviral drug developed
by Gilead initially for the treatment of diseases caused by Ebola and Marlburg viruses.
Interestingly, the nucleotide analogue Remdesivir is known to suppress CoV replication
through inhibition of this exoribonuclease and the RNA-dependent RNA polymerase.
Repurposed antiviral drugs make up most of the Chinese research,
with 9 Phase III trials on Remdesivir across several countries due to report by the end of April.
Repurposed antiviral drugs make up most of the Chinese research,
with nine phase III trials on Remdesivir across several countries due to report by the end of April.
Remdesivir was created
and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses.
Some early pretrial studies suggest Remdesivir may have a high genetic barrier to resistance.
There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
A dynamic review of clinical development for COVID-19 vaccine and drug candidates was in place, as of April 2020. Several existing antiviral medications are being evaluated for treatment of COVID-19,
including Remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir and lopinavir/ritonavir combined with interferon beta.